Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

Mayo Clinic

Status and phase: Completed; Phase 3

Conditions: Endothelial Dysfunction

Treatments: Drug: Atrasentan; Drug: atrasentan

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00271492

48-99

Details and patient eligibility

About

Qualifying patients who are scheduled for angiogram with endothelial function testing are approached to participate in this protocol (consent form reviewed with patient). Those who are willing to participate will have additional measurements taken during their angiogram as part of this protocol. Patients who are diagnosed with Endothelial Dysfunction as a result of a clinically indicated angiogram will be eligible to participate in a 6 month medication trial (Atrasentan vs. placebo - randomized, blinded trial). Patients are monitored closely during the 6 month trial via phone calls and blood testing for assessment. At the end of the 6 months they return to Mayo for a repeat angiogram to assess endothelial function for any changes or improvements.

Full description

Aim I: To determine the activity of the endogenous endothelin system in the coronary circulation in humans with coronary endothelial dysfunction and atherosclerosis risk factors. Aim II: To assess the potential of chronic endothelin receptor antagonists to improve preexisting coronary endothelial dysfunction and myocardial perfusion in humans and Aim III: To assess the effect of chronic endothelin receptor antagonism on the endogenous nitric oxide system in association with oxidative stress in humans with early coronary disease risk factors.

Enrollment: 200 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years and < 85 years
• Male or female

Exclusion criteria

• Left dominant circulation
• Heart failure with EF <40%
• Unstable angina
• MI or angioplasty of the LAD or circumflex with 6 months prior to entry into the study
• Use of radiographic contrast agent within 12 hours of entry into the study
• Use of investigational agents within one month of entry into the study
• Patients who require treatment with positive inotropic agents other than digoxin during the study
• Patients with cerebrovascular accident within 6 months prior to entry into the study
• Significant endocrine, hepatic, renal disorders; local or systemic infectious disease within 4 weeks prior to entry into study
• Pregnancy or lactation
• Mental instability
• Federal Medical Center patients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

200 participants in 2 patient groups, including a placebo group

I

Active Comparator group

Description:

Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.

Treatment:

Drug: Atrasentan

Drug: Atrasentan

2

Placebo Comparator group

Description:

placebo group to be compared to the actual medication

Treatment:

Drug: atrasentan